2025 - A Year in Lung Cancer Research

.jpg)

Lung cancer remains the leading cause of cancer deaths in the UK, but 2025 has offered new reasons for hope. With promising breakthroughs in targeted therapies, AI-enhanced screening, and early detection tools, this year marked a turning point in how we approach the disease. In this article, we explore some of the most impactful lung cancer research from 2025 and what it could mean for the future of screening, diagnosis, and care.

Key Facts

  • Lung cancer is the most common cause of cancer death in the UK, responsible for around 33,000 deaths annually.
  • More than 43,000 people are diagnosed with lung cancer in the UK each year.
  • Smoking remains the top risk factor, but up to 15 per cent of lung cancer cases occur in non-smokers.
  • The five-year survival rate in the UK is around 15 per cent for those diagnosed at stage three; however, early detection can improve rates to almost 65 per cent.
  • Low-dose CT (LDCT) scans are now the gold standard for lung cancer screening in high-risk groups.

Understanding Lung Cancer

Causes and Risk Factors

  • Smoking and secondhand smoke exposure: Smoking is the leading cause of lung cancer. Secondhand smoke contains many carcinogens and significantly increases lung cancer risk, particularly if exposure occurs early in life (before age 25) or is prolonged. Non-smokers exposed to secondhand smoke face a 20-30 per cent increased risk of lung cancer.
  • Radon gas: Radon, a naturally occurring radioactive gas found in soil and rocks, can accumulate in buildings and is the second largest cause of lung cancer after smoking. The risk is amplified in smokers exposed to radon.
  • Occupational exposure: Exposure to carcinogens like asbestos, silica, and diesel fumes in the workplace contributes to lung cancer risk. Occupational hazards are significant for those working in industries involving these substances.
  • Family history or genetic predisposition: Individuals with first-degree relatives who had lung cancer have around a two-fold increase in risk, likely due to genetic and shared environmental factors. Genetics play a role in some families with a strong lung cancer history.
  • Chronic respiratory diseases like COPD: Chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, raise the risk of lung cancer. Other lung diseases, such as idiopathic pulmonary fibrosis (IPF), also increase susceptibility to lung cancer.

Challenges in Early Detection

  • Symptoms can be vague and non-specific: Early lung cancer symptoms, such as persistent cough, breathlessness, chest pain, or fatigue, are easily mistaken for more benign conditions.
  • Asymptomatic early-stage disease: Many individuals with lung cancer experience no symptoms until the disease is advanced. Studies indicate that even when symptoms do occur, they may be subtle or ignored, leading to significant delays between symptom onset and diagnosis.
  • Limitations of chest X-rays: Traditional X-rays often miss small or central tumours, especially in the early stages, leading to underdiagnosis.

LDCT scans significantly improve the likelihood of detecting lung cancer at an early, more treatable stage, reducing mortality by up to 25 per cent. However, LDCT screening is typically targeted only to those at the highest risk and is not yet widely used in the UK.

Importance of Early Diagnosis

Early diagnosis of lung cancer is important because survival rates are dramatically higher when cancer is detected at Stage 1, with a 5-year survival rate ranging from 65 per cent to over 80 per cent in major population-based studies, compared to around 5 per cent for those diagnosed at Stage 4.

2025 Research Highlights

New Tools for Early Detection

  • The NHS has rolled out routine blood-based liquid biopsy testing for lung cancer, focusing on circulating tumour DNA (ctDNA). Around 15,000 patients could benefit each year, with over 1,600 already tested since April 2025.
  • UK trials are pioneering diagnostic breath tests that analyse volatile organic compounds (VOCs) released by tumour cells. Studies like the EVOLUTION trial at Royal Papworth Hospital use specialised probes to identify alcohol-based VOCs in the breath of lung cancer patients.
  • Clinical studies show that adding blood-based biomarkers to LDCT screening could improve early-stage detection rates by up to 60 per cent, enabling more high-risk individuals to be identified and treated appropriately.

AI in Lung Cancer Screening

  • NHS hospitals in Manchester use AI tools from Annalise.AI to analyse chest X-rays and CT scans, enabling urgent, high-risk scans to be flagged and processed more quickly, avoiding unnecessary further testing and cutting waiting times.
  • AI models show a much higher sensitivity (86-98 per cent) for detecting lung nodules compared to radiologists (68-76 per cent). These systems reduce missed cancers, especially when interpreting busy or complex scans.

Advances in Targeted and Immunotherapies

  • Immunotherapy targeting PD-1 (e.g., pembrolizumab, nivolumab) and PD-L1 (e.g., atezolizumab, durvalumab) is now routinely used as first-line or maintenance treatment, particularly for advanced and metastatic lung cancer.
  • Clinical trials demonstrate that adding immunotherapy to chemotherapy or as maintenance following radiation continues to offer significant survival benefits, especially for those without targetable mutations or with high PD-L1 expression.

Early Detection Tools: Still the Key to Progress

LDCT screening is a cornerstone of early lung cancer detection. It is recommended for adults aged 55-74 with a 30+ pack-year smoking history or those who quit within the past 15 years.

Recent NHS pilots and longitudinal studies in the UK and abroad show LDCT screening increases detection of stage I and stage II lung cancers by up to 20 per cent, compared to previous programs or conventional chest X-rays.

What You Can Do During Lung Cancer Awareness Month

Share Knowledge and Raise Awareness

  • Educate friends and family about important lung cancer symptoms such as persistent cough, unexplained weight loss, breathlessness, coughing up blood, chest pain, or long-term hoarseness.
  • Use social media hashtags to promote evidence-based information and reduce stigma.

Support Research and Trials

  • Consider donating to reputable research groups that drive advances in prevention, early detection, and treatment.
  • Encourage eligible friends and family to take part in lung screening programs and clinical research trials.

Book a Preventive Screening

  • If you are aged 50+ with a history of smoking, talk to your GP about arranging an LDCT. Early screening initiatives are now available in many UK regions and are proven to increase early-stage diagnosis.

Summary

2025 was a pivotal year in lung cancer research. Thanks to progress in early detection tools, personalised therapy, and AI-enhanced screening, lung cancer care is becoming faster, smarter, and more hopeful. Despite these advancements, early diagnosis remains the most powerful tool.